These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31043438)

  • 1. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides.
    Datta-Mannan A
    Drug Metab Dispos; 2019 Oct; 47(10):1100-1110. PubMed ID: 31043438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
    Hu S; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.
    Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R
    MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies.
    Grabowski T; Reijers JAA; Burmańczuk A; Chełmońska-Soyta A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):585-589. PubMed ID: 30810916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
    Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
    AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of altered endogenous IgG on unspecific mAb clearance.
    Fuhrmann S; Kloft C; Huisinga W
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities.
    Bittner B; Richter W; Schmidt J
    BioDrugs; 2018 Oct; 32(5):425-440. PubMed ID: 30043229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
    Lin JH
    Curr Drug Metab; 2009 Sep; 10(7):661-91. PubMed ID: 19702530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.
    Curreri AM; Kim J; Dunne M; Angsantikul P; Goetz M; Gao Y; Mitragotri S
    Adv Sci (Weinh); 2023 Mar; 10(7):e2205389. PubMed ID: 36642846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of therapeutic monoclonal antibodies.
    Dirks NL; Meibohm B
    Clin Pharmacokinet; 2010 Oct; 49(10):633-59. PubMed ID: 20818831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.
    Kivitz A; Segurado OG
    Expert Rev Med Devices; 2007 Mar; 4(2):109-16. PubMed ID: 17359217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.